Inhaltsübersicht

Klinische Studien mit möglichem Studieneinschluss

DeCOG-MM-PAL11

The IPI - Multibasket Trial in advanced uveal melanoma: Prospective clinical phase II multibasket study in Melanoma patients with advanced disease

ADO ChemoSensMM

Prospectively randomized phase III study of an individualized sensitivity-directed combination chemotherapy versus DTIC as first-line treatment in stage IV metastatic melanoma

AB08026 AB Science

A prospective, multicenter, randomized, open-label, active-controlled, two-parallel groups, phase 3 study to compare the efficacy and safety of masitinib at 7.5 mg/kg/day to dacarbazine in the treatment of patients with non-resectable or metastatic stage 3 or stage 4 melanoma carrying a mutation in the juxta membrane domain of c-kit

ADO - Sentinel Studie

Kontrollierte und prospektiv randomisierte Therapiestudie zum Vergleich einer radikalen Lymphadenektomie versus Beobachtung bei Patienten mit malignem Melanom >1,0 mm Tumordicke und positivem Wächter-Lymphknoten

GSK PRAME

An open, dose-escalation Phase I/II study to assess the safety, immunogenicity and clinical activity of recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic as first-line treatment of patients with PRAME-positive metastatic melanoma

Klinische Studien aktuell kein Studieneinschluss möglich

GSK MEK114267

A phase III randomized, open-label study comparing GSK1121212 to chemotherapy in subjects with advanced or metastatic BRAF V600E/K mutation-positive melanoma

ROCHE MO25515

An open-label, multicenter expanded access study of RO5185426 in patients with metastatic melanoma

BMS CA 184-029

Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma: a randomized, double-blind Phase III trial of the EORTC Melanoma Group

GSK Predict

Predictive gene signature fore REsponse to recMAGE-A3 in unresecteD metastatIc CuTaneous melanoma Recombinant MAGE-A3 protein (recMAGE-A3) combined with the AS15 immunological Adjuvant System

GSK Derma

A double-blind, randomized, placebo-controlled phase III study to assiss the efficacy of recMAGE-A3+AS15 ASCI as adjuvant therapy in patients with MAGE-A3 positive resected stage III melanoma

BMS CA 184-025

a multicenter, open-label, phase II study of Ipilimumab (MDX-010) extended-treatment Monotherapy or follow-up for patients previously enrolled in Ipilimumab (MDX-010) protocols

BMS CA 184-024

a multicenter, randomized, double-blind, two-arm, phase III Study in Patients with untreated stage III (unresectable) or IV Melanoma receiving Dacarbazine plus 10 mg/kg of Ipilimumab (MDX-010) vs. Dacarbazine with placebo